{"organizations": [], "uuid": "c53d6cb01853208c78ad2f200bd16d733f1c2870", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180502.html", "section_title": "Archive News &amp; Video for Wednesday, 02 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-acorda-therapeutics-reports-q1-non/brief-acorda-therapeutics-reports-q1-non-gaap-earnings-per-share-of-0-14-idUSASC09YVR", "country": "US", "domain_rank": 408, "title": "BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.019, "site_type": "news", "published": "2018-05-02T18:08:00.000+03:00", "replies_count": 0, "uuid": "c53d6cb01853208c78ad2f200bd16d733f1c2870"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-acorda-therapeutics-reports-q1-non/brief-acorda-therapeutics-reports-q1-non-gaap-earnings-per-share-of-0-14-idUSASC09YVR", "ord_in_thread": 0, "title": "BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "acorda therapeutics inc", "sentiment": "negative"}, {"name": "acorda", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "acorda therapeutics", "sentiment": "none"}, {"name": "ampyra", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2 (Reuters) - Acorda Therapeutics Inc:\n* ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR FIRST QUARTER 2018\n* Q1 NON-GAAP EARNINGS PER SHARE $0.14\n* Q1 REVENUE $103 MILLION * Q1 EARNINGS PER SHARE VIEW $0.47 — THOMSON REUTERS I/B/E/S\n* Q1 REVENUE VIEW $129.9 MILLION — THOMSON REUTERS I/B/E/S * EXPECTS TO END 2018 WITH A PROJECTED YEAR-END CASH BALANCE IN EXCESS OF $300 MILLION\n* FDA ACCEPTED INBRIJA(LEVODOPA INHALATION POWDER) NDA; PDUFA DATE OCTOBER 5, 2018\n* ACORDA THERAPEUTICS SAYS EXPECTS TO MAINTAIN EXCLUSIVITY OF AMPYRA AT LEAST THROUGH JULY 30, 2018\n* ACORDA THERAPEUTICS - 2018 RESEARCH AND DEVELOPMENT EXPENSES EXPECTED TO BE $100 MILLION TO $110 MILLION AND INCLUDE MANUFACTURING EXPENSES ASSOCIATED WITH INBRIJA Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-02T18:08:00.000+03:00", "crawled": "2018-05-03T12:07:29.005+03:00", "highlightTitle": ""}